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Limb budDuring development, the mammalian embryo must integrate signals to control growth and proliferation. A
failure in the ability to respond to mitogenic stimuli can cause embryonic growth restriction. We have
identiﬁed a mouse mutant, l11Jus15, from a mutagenesis screen that exhibits growth defects and late-
gestation lethality. Here we demonstrate that this phenotype results from a mutation in the Mediator
complex gene Med31, which causes degradation of Med31 protein. The Med31 mutant phenotype is not
similar to other Mediator complex mouse mutants, and target genes of other Mediator proteins are
expressed normally in Med31 mutants, suggesting that Med31 has distinct target genes required for
mammalian development. Med31 mutant embryos have fewer proliferating cells than controls, especially in
regions that expand rapidly during development such as the forelimb buds. Likewise, embryonic ﬁbroblast
cells cultured from mutant embryos have a severe proliferation defect, as well as reduced levels of the cell
cycle protein Cdc2. Med31 mutants have normal limb bud patterning but defective or delayed
chondrogenesis due to a lack of Sox9 and Col2a1 expression. As the Mediator complex is a transcriptional
co-activator, our results suggest that Med31 functions to promote the transcription of genes required for
embryonic growth and cell proliferation.(K.E. Hentges).
ll rights reserved.© 2010 Elsevier Inc. All rights reserved.Introduction
During development, many factors are required for the growth of
the mammalian embryo. At a molecular level, embryonic cells must
integratemitogenic signals to promote cell proliferation. Many groups
of genes are required for embryonic growth, ranging from those
involved in the cell cycle to transcription factors that promote cell
proliferation in speciﬁc organs or tissues (Brodsky and Christou,
2004). Despite the expectation that many diverse genes are required
for embryonic growth, relatively few embryonic growth control genes
have been identiﬁed in mammals (Efstratiadis, 1998; Han and Carter,
2001).
The mouse is an important experimental model for the study of
embryonic growth and intrauterine growth restriction. Genetic
manipulations in the mouse enable the deletion of genes from the
embryo, placenta, or both, allowing embryonic and extra-embryonic
requirements for selected genes to be evaluated. Additionally,
mutagenesis screens in the mouse provide a phenotype driven
approach to identify genes required for developmental processes in
an unbiased manner. We have isolated a mutant, l11Jus15, from amouse balancer chromosome mutagenesis screen that demonstrates
cell proliferation and growth defects during development (Kile et al.,
2003). Using a positional cloning strategy, we identiﬁed a mutation in
the Mediator complex protein Med31 in the l11Jus15 mutant mouse.
The Mediator complex is a general transcriptional co-activator
required for transcription from RNA polymerase II promoters. The
Mediator complex contains asmany as 30 proteins (Malik and Roeder,
2005) and shows conservation from yeast through human (Blazek et
al., 2005). Interactions between individual Mediator proteins and
nuclear hormone receptors, as well as other transcription factors, have
been identiﬁed (Beyer et al., 2007; Chen and Roeder, 2007; Ge et al.,
2008; Gordon et al., 2006; Rau et al., 2006; Stumpf et al., 2006; Zhu et
al., 1997). These ﬁndings suggest that the Mediator complex serves as
a bridge between gene-speciﬁc activators and the RNA polymerase to
initiate transcription from Pol II promoters (Blazek et al., 2005).
Med31was ﬁrst identiﬁed in yeast (called Soh1) as a suppressor of
the hyperrecombination mutant hpr1 (Fan et al., 1996; Fan and Klein,
1994) and is a component of the Mediator complex in Saccharomyces
cerevisiae and Schizosaccharomyces pombe (Linder and Gustafsson,
2004). Med31 is located in the middle region of the Mediator complex
and binds Med10 and Med21/Srb7 (Guglielmi et al., 2004). Med31 is
one of the most conserved proteins in the Mediator complex and, in
yeast, acts as a positive regulator for transcription of target genes
(Koschubs et al., 2009). No speciﬁc transcription factor interaction
partners have been identiﬁed for the Med31 protein, distinguishing it
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mouse mutants (Ito et al., 2002, 2000).
Surprisingly, Med31 is not essential in S. cerevisiae (Fan and Klein,
1994) although it is required for septation in the ﬁssion yeast S. pombe
(Grallert et al., 1999). In Drosophila, maternal Med31 is required for
the establishment of cell fate and anterior–posterior axis formation
during embryogenesis (Bosveld et al., 2008). Here we show that
Med31 mutant mouse embryos have defects in cell proliferation and
are smaller than control littermates from mid-gestation. This mutant
phenotype is different to the phenotypes observed from targeted
deletions of Med1 and Med24 (Ito et al., 2002, 2000). An analysis of
the target genes of other Mediator complex proteins demonstrates
that Med31 mutants express these target genes at levels comparable
to wild-type littermates, allowing us to conclude that Med31 target
genes are distinct from those of other Mediator complex proteins.
Fibroblasts isolated from mutants also exhibit a proliferation defect
and lack the cell cycle protein cdc2.Med31mutant embryos also have
reduced expression of cyclin B and mTOR, genes involved in cell
proliferation. Sox9 and Col2a1, genes required for limb bud prolifer-
ation, are not expressed in Med31 mutant limb buds. These
experiments therefore identify cdc2, cyclin B, mTOR, Sox9, and
Col2a1 as putative Med31 target genes. These results demonstrate
that Med31 is required for mammalian development and regulates
genes that promote proliferation during embryogenesis.
Materials and methods
Embryo dissection and analysis
l11Jus15mutation carriers were set up for timed matings. The day
of the vaginal plug was considered as E0.5. At the desired time point,
embryos were dissected out of their decidua and placed on ice for
30 min. Prior to ﬁxation, embryos were imaged while submerged in
PBS using a Leica MZ6 microscope and DFC420 camera.
Genotyping, mutation mapping, and Med31 sequencing
Genomic DNA obtained from ear punches of adultmice or yolk sacs
of embryos was subjected to PCR to differentiate between C57BL/6
(mutant) and 129S5 (wild-type) strains of mice. For mutation
mapping, and some experimental crosses, mice were bred to wild-
type 129S5 mice to remove the balancer chromosome. Mice without
the balancer chromosome were mated and their offspring genotyped
to determine if they were C57BL/6, 129S5, or heterozygous in the
‘balancer region’. Adult mice with a chromosome that was partially of
C57BL/6 and partially of 129S5 background in the chromosome 11
balancer regionwere designated as ‘recombinant’. Out of a total of 458
genotyped mice, 82 were found to be recombinant (17.9%).
Recombinants were mated with l11Jus15 mice and offspring geno-
typed at 4 weeks of age. The presence of homozygous C57BL/6
offspring in a litter demonstrated the absence of the mutation causing
the l11Jus15 phenotype. The absence of any homozygous C57BL/6
pups indicated that the mutation was present. Genotyping primer
sequences andMed31 sequencing primers are listed in Supplementary
Table 1. PCR products were puriﬁed by precipitation and sequenced
using Big Dye 1.1 (ABI).
Quantitative real-time PCR
RNA was prepared from individual tissues from CD1 E15.5
embryos, or E10.5 wild-type or l11Jus15 mutant whole embryos,
using TriReagent (Sigma). Five micrograms of RNA from each tissue
was treated with RNase-free DNaseI (Promega) and then reverse
transcribed with random primers (Promega) and BioScript reverse
transcriptase (BioLine). cDNA was added to quantitative real-time
PCR reactions using a qPCR core kit (RT-QP73-05, Eurogentec) and thevalidated Med31 TaqMan assay (Mm00651937_g1, Applera UK), or
SYBR green reagent. Each reaction was performed on three separate
embryos for biological replicates. For Med1, Med28, and Med31 target
gene qPCR, E14.5 fetal organ RNA was isolated from at least three
embryos of each genotype. GATA-1 target gene primer sequences
were provided by Tilman Borggrefe (personal communication).
Published qPCR primer sequences for Med28 targets (Beyer et al.,
2007), cyclin B (Tschop and Engeland, 2007), and mustn1(Gersch and
Hadjiargyrou, 2009) were used as described. mTOR primer sequences
were forward: TACGTCACCATGGAGCTTCGA and reverse:
CAAATCTGCCAATTCTGGTGG. All reactions were normalized to
GAPDH levels using primer sequences forward: AACTCGGCCCCCAA-
CACT and reverse: TCTAGGCCCCTCCTGTTATTATG. Each qPCR reaction
was performed in triplicate for technical replicates.
Whole mount immunohistochemistry and cell counting
Dissected embryos (Supplemental Information) were ﬁxed in 4%
paraformaldehyde (PFA) in PBS for 1 h and stored in 100% methanol.
Rehydrated embryos were stained with primary antibody: anti-CD31
at 1:100 dilution (BD Pharmingen; cat 550274); anti-phospho-
histone H3 at 1:100 dilution (Upstate Biotechnology; cat 06-570)
for 1 h at room temperature. Secondary antibody was used at 1:250
dilution, and staining was developed using the VECTASTAIN Elite ABC
Kit (Vector Laboratories). Proliferating cells were counted using
Image Pro Plus 6.2 software (Media Cybernetics) and analyzed
statistically using SPSS version 15 (SPSS Inc.).
MEF cell cultures and growth curve assays
Fibroblast isolation and culture conditions are listed in Supple-
mental Information. For growth curve experiments, P5 cells were
plated in 6-well plates at 2.5×104 cells per well and counted using a
hemocytometer after 1, 3, 5, and 7 days. Mice without the balancer
chromosome were used in these crosses, so that wild-type 129S5
embryos were recovered along with heterozygotes and l11Jus15
mutants.
Generation of FLAG-Med31 constructs
Mouse Med31 cDNA was obtained from Gene Services (Cam-
bridge, UK) in the pCMV-SPORT6 vector (IMAGE Clone 5709831). PCR
products of full-length Med31 cDNA were generated using primer
sequences Med31-NotI-GCGGCCGCGATGGCTGCGGCCGT and Med31-
SalI-AGAGTCGACCCTAAGAGCCTGACCTGG for cloning into pFLAG-
CMV2 (Sigma). Primers L15-01-GCAGATTCTGCACTGGTAGCAC-
TACTCTCG and L15-02-CCGAGAGTAGTGGAACCAGTGCAGAATCTG
were used for site-directed mutagenesis to create the mutant version
ofMed31. Pfu Ultra polymerase and buffer (Stratagene) were used for
PCR mix according to manufacturer's instructions. Cycling conditions
for site directed mutagenesis were as follows: 95 °C 30 s, 12 cycles of
95 °C 30 s, 55 °C 1 min, 68 °C 5 min. DpnI was then added to the PCR
reaction for 2 h at 37 °C to digest plasmid DNA, but not the PCR
product. Following digestion, the DNA was transformed, and mini-
preps performed on all colonies. The presence of the Med31 ENU
mutation was conﬁrmed by sequencing.
HEK293 cell culture and transfections
HEK293 cells were cultured in T75 ﬂasks and passaged at
conﬂuency. Culture media was as follows: DMEM (BioWhittaker),
10% FCS (BioWhittaker), 1xPen/Strep (BioWhittaker), 1× L-glutamine
(BioWhittaker). For transfections, cells were passaged into 6-well
plates at 2×106 cells per well in antibiotic free media. The next day, at
80–90% conﬂuency, cells were transfected using Lipofectamine 2000
(Invitrogen). To block proteasome activity 10 μm Lactacystin
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48 h post-transfection by resuspending cell pellets in lysis buffer
(50 mM HEPES, pH7.5; 10 mM EDTA; 150 mM NaCl; 1% NP40) plus
inhibitors (complete protease inhibitor and PhosSTOP cocktails;
Roche Applied Science), incubating for 1 h on ice, and then storing
at −80 °C.
SDS-PAGE and Western blotting
Protein concentration of cell lysate was measured using the Bio-
Rad Protein Assay (cat no. 500-0006). For SDS-PAGE, 50 μg of protein
lysate was loaded onto a 15% polyacrylamide gel. Membranes were
blocked overnight in 5% milk in TBS at 4 °C, incubated in primary
antibody: anti-Med31 (ag9008, Proteintech), anti-FLAG M2 (Sigma),
anti-β-actin (Sigma), anti-Cdc2 (sc-54, Santa Cruz Biotechnology),
anti-Cdk2 (sc-163, Santa Cruz Biotechnology), or anti-Srb7 (sc-12459,
Santa Cruz Biotechnology) at 10 μg/ml for 1 h at room temperature
(Med31 at 1:1000 dilution), and washed and incubated in secondary
antibody at 1:20,000 dilution for 1 h at room temperature. ECL
solution (Amersham) was used to detect signal from blots.
Whole mount in situ hybridization
Following ﬁxation overnight in 4%PFA, embryos were processed
for whole mount in situ hybridization as previously described
(Henrique et al., 1995). Anti-sense probes were synthesized from
linear template DNA by incubation with RNA polymerase (Roche),
digoxygenin nucleotidemix (Roche), and transcription buffer (Roche)
for 2 h at 42 °C. Probes were puriﬁed by precipitation and added to
hybridization mix at a concentration of 0.5 μg/μl.
Histology
Embryos were ﬁxed in Bouin's ﬁxative overnight. Embryos were
then dehydrated in Xylene, embedded in parafﬁn, and sectioned at
7 μm. After sectioning, parafﬁn was removed from sections by
washing 3×5 min in Xylene. Sections were then rehydrated through
a decreasing series of ethanol washes, stained in hemotoxylin and
eosin, and mounted for analysis.
Skeletal analysis
Skin and organs were removed from E18.5 embryos. Embryos
were dehydrated in 100% ethanol for 4 days, incubated in acetone for
3 days, and then stained with 0.1% alizarin red and 0.3% alcian blue in
a mixture of 5% acetic acid, 95% ethanol for 10 days at room
temperature in the dark. Skeletons were then rinsed in 95% ethanol,
incubated for several hours in 1.8% KOH, and then placed in 0.3% KOH
overnight. Skeletons were stored in 100% glycerol and transferred to
50% glycerol, 50% PBS for imaging.
Results
l11Jus15 mutants have growth defects
l11Jus15 mutants were initially recovered from a balancer
chromosome mutagenesis screen designed to identify recessive
embryonic lethal mutations without any bias towards phenotype or
time of death (Kile et al., 2003). A detailed phenotypic analysis of
l11Jus15 mutant embryos revealed that mutants and heterozygous
littermates were comparable in size and development through
embryonic day (E) 8.5 (Fig. 1A, B). At E9.5, 57% of mutants were
smaller and delayed in development compared to littermates
(Fig. 1C–E). At E10.5, all mutants appeared reduced in size compared
to heterozygous littermates (Fig. 1F–H). Mid-gestation mutants
appear delayed in development by approximately 24 h relative tolittermates (Fig. 1I, J). We have previously reported observing edema
and spina biﬁda in mutant embryos recovered at E15.5 (Hentges et al.,
2006). However, the penetrance of these phenotypes has decreased
greatly as we have out-crossed the mutants to 129S5 mice, suggesting
dependence on genetic background. Mutants are rarely recovered
after E16.5, indicating late-gestation lethality (Table 1). Embryos that
survive until E18.5 are smaller and paler than littermates (Fig. 1K, L),
and we have not observed any mutants alive at birth. Thus, the
gene that is mutated in l11Jus15 mice is required for mammalian
development.
Positional cloning of the l11Jus15 mutation
Because the l11Jus15 mutant was isolated from a balancer
chromosome mutagenesis screen (Kile et al., 2003), the causative
mutation was initially mapped to a 35-Mb region of mouse
chromosome 11. Meiotic mapping of the l11Jus15 phenotype allowed
the critical region to be reduced to a 2.8 MB interval between the
simple sequence length polymorphism (SSLP) marker D11MIT31, and
the single nucleotide polymorphism (SNP) marker SNP rs29451074
(Fig. 2A). Sequencing of all genes in this region resulted in the
identiﬁcation of a mutation in the fourth exon of the mouse Med31
gene (Fig. 2B). This mutation results in a predicted truncation of the
Med31 protein at amino acid 105, eliminating the ﬁnal 26 amino acids
in the protein. No other coding region mutations were detected in
candidate gene sequencing. Based on our identiﬁcation of this
mutation, we will refer to the l11Jus15 mutant line as the Med31
mutant mouse.
The Med31 mutation causes protein degradation
The predicted truncation of Med31 does not delete any annotated
functional domains (Interpro database, www.ebi.ac.uk/interpro).
Pairwise BLAST analysis (http://blast.ncbi.nlm.nih.gov/Blast.cgi)
revealed that S. cerevisiae and mouse Med31 amino acid sequences
are 60% similar when conservative substitutions are allowed,
indicating that the two proteins likely have the same functional
domains. Comparison with the recently solved crystal structure for
the S. cerevisiae Med31 homolog indicates that the C-terminal region
of the protein is unstructured (Koschubs et al., 2009), and therefore, it
is unlikely that the l11Jus15 truncation eliminates any speciﬁc protein
activity. We therefore evaluated whether the mutation might have an
effect on transcript stability in mutants. Semi-quantitative RT-PCR
analysis indicates that mutants express Med31 at levels similar to
heterozygous littermates (Fig. 2C). We next examined the Med31
mutant protein using a polyclonal antibody generated against full-
length Med31. Western blotting revealed that mutants lack Med31
protein, and heterozygotes have approximately half as much protein
as wild-type embryos (Fig. 2D). These results indicate that the
l11Jus15mutation produces a null allele of Med31. The lack of Med31
protein in mutants was surprising, since based on the sequence
analysis of the Med31 mutation, we predicted that our mutant mice
would produce a truncated protein approximately 3 kDa smaller than
the wild-type Med31 protein. To model the effects of theMed31 point
mutation, we generated epitope-tagged versions of the Med31
mutant protein and a wild-type Med31 control. Following transfec-
tion assays in HEK293 cells, we detected the wild-type tagged-
protein, but not the mutant protein, through Western blotting
(Fig. 2E), suggesting that the Med31 mutation causes protein
degradation. Blocking proteasome activity with lactacystin allows
the accumulation of the truncated Med31 protein (Fig. 2E), conﬁrm-
ing that the mutation results in degradation of the protein.
As Med31 has been shown to be a direct binding partner for
Med21/Srb7 (Guglielmi et al., 2004), we also wondered whether Srb7
protein levels might be reduced in our Med31 mutant due to a lack of
protein–protein interactions with Med31. Western blotting for Srb7
Fig. 1.Med31mutant embryos have a growth defect. At E8.5, heterozygous (A) and homozygous mutant (B) littermates are of comparable size and morphology. E9.5 heterozygotes
(C) display normal development and are larger than mutants (D, E). Some mutants appear normal (D), while others are clearly abnormal for this stage of development (E). By E10.5,
heterozygous littermates (F) are larger than all mutant embryos (G, H), which again display a small range of morphology and size. At E14.5, heterozygous littermates are well
developed normally (I), while mutants are much smaller (J). At very late stages of gestation, heterozygous littermates (K) are larger than mutants (L), though very few mutant
embryos survive to this stage of development. Note that the E18.5 mutant embryo head (L) is similar in size to the E18.5 control head (K), while the body size of the mutant is
reduced compared to that of the littermate control. Scale bars: A, B=200 μm; C–H=500 μm, and I–L=2 mm.
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and wild-type controls (Fig. 2F), as conﬁrmed by densitometry
analysis of Srb7 band intensity normalized to β-actin band intensity
(t-test, p=0.49).
Med31 developmental expression pattern
As the developmental expression pattern of Med31 was unknown,
we performed quantitative RT-PCR to determine the expression
pattern of Med31 in embryonic tissues. We found that Med31 was
expressed in all tissues examined, although expression levels vary in
individual tissues. The highest level of expression ofMed31 is found in
the brain, with approximately 5-fold greater expression of Med31
than in the heart or placenta (Fig. 2G). Detectable levels of expressionTable 1
The Med31 mutation causes late-gestation lethality.
Stage Wild Type Heterozygote Mutant
E8–E10 26 51 39
E11–E14 37 55 24
E15–E18 27 77 16were also found in the limbs, lungs, and the liver. It is likely that the
variation in Med31 expression results in a differential expression of
Med31 target genes in speciﬁc embryonic tissues.
The Med31 phenotype is distinct from other Mediator mutants
OtherMediator complex genes, such asMed1/Trap220 andMed24/
Trap100, have been inactivated by targeted deletion in the mouse,
demonstrating early gestation lethality due to cardiac defects (Ito
et al., 2002, 2000). We therefore examined cardiac development in
ourMed31mutants. At E9.5 we ﬁnd no defects in the expression of the
cardiac transcription factor Nkx2.5 in mutants (Fig. 3A, B). As the
Med31 mutants survive until late gestation, we investigated the
possibility that they develop cardiac defects at a later time point than
Med1/Trap220 and Med24/Trap100 mutants. Histological analysis
revealed no late-gestation abnormalities in E14.5 Med31 mutant
hearts (Fig. 3C, D). Thus, theMed31mutant phenotype is distinct from
other Mediator mutants.
We also examined whether Med31 mutants had similar defects in
gene expression as other Mediator complex mutants. The Mediator
complex protein Med1/Trap220 has been identiﬁed as an interaction
partner for GATA-1 and activates GATA-1 target genes required for
erythropoiesis (Stumpf et al., 2006). Additionally, Med28 has been
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Fig. 3.Med31mutants have a phenotype distinct from other Mediator complex mouse mutants. (A) Control littermate expresses Nkx2.5 in the developing heart at E9.5. (B) Med31
mutants express Nkx2.5 at E9.5 in the developing heart in a pattern comparable to controls (n=2). (C) Control littermates at E14.5 have no gross morphological cardiac defects. (D)
Med31mutants have normal cardiac morphology at E14.5 (n=3). (E) Target genes of other Mediator complexmutants are not mis-expressed inMed31mutants. Wild-type embryos
are shown in purple, Med31 mutants are shown in yellow. The units on the y-axis are arbitrary and represent relative expression levels.
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SM22α and SM-αActin (Beyer et al., 2007). To determine if Med31 acts
on the same targets as Med1/Trap220 and Med28, we examined the
expression of the GATA-1 target genes Alas2, Band3, Band4.1, Eraf
(Welch et al., 2004), and the smooth muscle genes SM22α and SM-
αActin inMed31mutants. We found that there were no differences in
expression of any of these genes in Med31 mutants (Fig. 3E). These
results suggest that targets of other Mediator complex proteins are
expressed in mutants lacking Med31 function.Med31 mutants have proliferation defects
As Med31 mutant embryos are smaller than heterozygous
littermates, we assessed cell proliferation in mutants during devel-
opment. We performed whole mount immunohistochemistry to
detect the presence of phospho-histone H3, a marker of mitotic cells
(Fig. 4A, B). As the mutant phenotype becomes apparent from E9.5–
E10.5, we examined proliferation at these ages. The number of stained
cells per unit of tissue area was determined for mutants andwild-type
controls. No differences were observed at E9.5. At E10.5 signiﬁcant
differences were detected for regions of the head, trunk, and forelimb
bud, with the most pronounced difference in the forelimb bud
(Fig. 4C, F). This is most likely due to the rapid expansion of the limb
bud at this stage of development (Fernández-Terán et al., 2006). As it
is possible that impaired proliferation results from extrinsic factors
such as a lack of nutrients, we also examined vascular development in
Med31 mutant embryos. Using the marker CD31, we found no
differences between wild-type and Med31 mutant embryos (Fig. 4D,Fig. 2. The L11Jus15 mutant phenotype results from a point mutation in the Mediator com
chromosome 11 containing the Med31 gene. The inset shows the L11Jus15 candidate region
revealed a C to T point mutation in exon 4 of theMed31 gene, resulting in a premature stop c
Med31 is transcribed at levels comparable to that of the wild-type gene. Four heterozygou
relative to the l11Jus15 mutant with the lowest expression. The difference in expression le
Med31 protein is absent in l11Jus15mutant embryos and present at approximately 50% of w
Med31 (lanes 2 and 3) or the ENU point mutant (lanes 4 and 5) into HEK293 cells reveals an a
of wild-type protein (lanes 6 and 7) and results in detectable levels of the FLAG-tagged M
Transfection of empty vector (NT) does not show any bands because the FLAG tag alone is to
protein loading. (F) Mutant embryos have Srb7 protein at levels similar to wild-type litterm
Expression levels are reported relative to expression in the heart, which was the tissue witE, G, H), indicating that the lack of cell proliferation is not a result of
impaired blood supply in mutant embryos.
The absence of vascular defects suggests that Med31 mutant cells
have an intrinsic defect in proliferation. To evaluate this, we cultured
primary mouse embryonic ﬁbroblast (MEF) cells from embryos and
generated 1-week growth curves for wild-type, heterozygote, and
Med31 mutants (Fig. 4I). Cells isolated from Med31 mutants
demonstrate a statistically signiﬁcant growth defect (ANOVA and
post hoc test, pb0.05). As the cultured cells could obtain all required
nutrients from the media, the proliferation defects observed in
mutant ﬁbroblasts suggests that Med31 mutants have an intrinsic
cell proliferation defect. Next, we compared levels of the cell cycle
proteins Cdc2 and Cdk2 in wild-type and mutant cells (Fig. 4J). Cdc2
protein levels were much reduced in the majority of mutant samples
(Fig. 4J). Notably, the mutant cells with the highest Cdc2 levels
(marked with #) were growing at an unusually high rate for cells of
this genotype, although they were not growing as quickly as wild-
type cells. This ﬁnding suggests that Cdc2 expression is necessary but
not sufﬁcient for normal growth in MEF cells. A similar analysis of
Cdc2 and Cdk2 protein levels in Med31 mutant embryos revealed no
signiﬁcant differences between wild-type and mutant embryos
(Fig. 4K, L). This discrepancy may result from the presence of cell
types other than ﬁbroblasts in whole embryo extracts, which may not
exhibit a similar amount of reduced cell proliferation as pure
ﬁbroblast cultures.
Interactions between Cdc2 and Cyclin B promote the onset of M
phase and mitosis (reviewed in Budirahardja and Gonczy, 2009). As
we found alterations in Cdc2 levels in the Med31 mutant, we also
wanted to explore whether Cyclin B was normally expressed. Usingplex gene Med31. (A) The L11Jus15 mutation was mapped to a 6 cM region of mouse
in relation to the whole balancer chromosome interval. (B) Genomic DNA sequencing
odon. Note that in heterozygotes, two peaks are observed. (C) qPCR reveals that mutant
s and 3 mutant embryos at E10.5 were examined, and expression levels are reported
vels is not statistically signiﬁcant (t-test, p=0.44). (D) Western blotting reveals that
ild-type levels in heterozygotes. (E) Transfection of a FLAG-tagged version of wild-type
bsence of mutant protein. Blocking protein degradation with lactacystin increases levels
ed31 point mutant protein (lanes 8 and 9). Mutant protein is truncated, as predicted.
o small to detect. Re-probing blots with anti-β-actin antibody demonstrated equivalent
ates (t-test, p=0.49). (G) qPCR results show thatMed31 expression is highest in brain.
h the lowest Med31 expression. The units on the y-axis are arbitrary.
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Med31 mutant embryos (Fig. 4M). Due to the pronounced limb bud
proliferation defects in Med31 mutants, we also examined two other
genes associated with proliferation in the embryonic limb bud, mTOR
and Mustn1. mTOR has a positive role in chondrocyte maturation,
proliferation, cartilage production, and cell growth during limb
development (Rokutanda et al., 2009). Additionally, the ﬂat-top
mutant mouse, an ENU-induced mTOR mutant (Hentges et al.,
2001), lacks outgrowth of the limb buds during early development
(K. Hentges, unpublished observation). Consistent with the prolifer-
ation defects detected in Med31 mutant limb buds, we found a
signiﬁcant reduction in mTOR expression in Med31 mutants as
compared to control littermates (Fig. 4M). Mustn1 is expressed in
the embryo from E10.5 in areas of active chondrogenesis. Silencing
Mustn1 expression in chondrocytic cell lines reduces proliferation
rates and impairs the expression of chondrogenic marker genes
(Gersch and Hadjiargyrou, 2009). However, there was no difference in
Mustn1 expression levels between Med31 mutants and controls
(Fig. 4M), indicating that limb proliferation defects inMed31mutants
are independent of Mustn1. These experiments identify cyclin B and
mTOR as additional putative Med31 target genes.
The role of Med31 in limb development
The observation that limb bud proliferation was signiﬁcantly
reduced in Med31 mutants led us to examine limb development in
greater detail. We began our investigationwith an expression analysis
of limb bud markers during early development. We found that Fgf8,
which is required for limb bud patterning and is expressed in the
apical ectodermal ridge (AER) (Lewandoski et al., 2000), was
expressed normally in Med31 mutant embryos (Fig. 5A, B). Signals
from the AER promote cell proliferation in the developing limb bud
(Shimizu et al., 2007). The ﬁnding that Fgf8 is expressed in Med31
mutants indicates that AER speciﬁcation is unaffected by the absence
of Med31.
To extend our analysis of limb bud development inMed31mutants
we examined the expression of Sox9, a transcription factor required
for chondrocyte condensation and outgrowth of the limb (Akiyama
et al., 2002). Sox9 is not expressed at detectable levels in Med31
mutant limb buds at E10.5 (Fig. 5C, D). It is interesting to note that in
zebraﬁsh Sox9 is a target of the Mediator complex protein Med12/
Trap230 in the developing neural crest and ear, but not the ﬁn (Rau
et al., 2006). Recently, it has been demonstrated that Sox9 is required
for invagination of the otic placode in the mouse (Barrionuevo et al.,
2008). We therefore examined ear development in our Med31
mutants. We found no defects in ear development (Fig. 5E, F),
consistent with the expression of Sox9 in the otic placode in Med31
mutants (Fig. 5D). Therefore, it is likely that Med31 function is
required for Sox9 expression in the developing mouse limb bud, but
not in other regions of the embryo.
Mouse mutants with haploinsufﬁciency of Sox9 also have reduced
levels of Collagen II (Col2a1), leading to abnormalities in skeletal
structures derived from cartilage precursors (Bi et al., 2001).
Additionally, Sox9 activates a chondrocyte-speciﬁc enhancer in the
Col2a1 promoter in cooperation with other Sox proteins (LefebvreFig. 4. Med31 mutants have reduced proliferation. Mutant embryos have comparable pho
heterozygous littermates (measurements made were number of positively stained cells per
mutant limb buds (C) as compared to wild type (F). Immunohistochemistry for CD31/PECAM
in both the head (D, G) and the trunk/forelimb bud (E, H). (I) One-week growth curves are
embryonic ﬁbroblast (MEF) cells derived from E14.5 embryos. There are signiﬁcant differenc
and 7 (measurements made were number of cells per well; ANOVA, pb0.05). Post hoc tests
differences between both and mutant cells (pb0.05). (J) Western blotting of MEF whole cell
single mutant sample (#) had Cdc2 levels comparable to that of wild-type samples. (K) W
littermates (t-test, p=0.24). (L) Whole embryos demonstrate that Cdk2 levels are similar in
reveals that Cyclin B expression is reduced in Med 31 mutants (t-test, p=0.07), mTOR e
expression is not affected (t-test, p=0.98). Scale bars: C, F=100 μm and D, E, G, H=500 μet al., 1998). Due to the ﬁnding that Sox9 expression was disrupted in
Med31 mutants, we also analysed Col2a1 expression. Consistent with
the results for Sox9 expression, we found that Med31 mutants also
lack Col2a1 expression in the developing limb bud (Fig. 5G, H).
We also examined limb morphology later in development. We
found that inMed31mutants at E14.5 there was defective ossiﬁcation
of the bones of both the forelimbs (Fig. 5I–L) and hindlimbs. By E18.5,
Med31 mutants have progressed to form bone in the skeleton,
although the majority of bones are smaller than in control littermates.
This size difference is especially prominent in the rib cage and limbs,
but less notable in the skull (Fig. 5M, N). The digits also show reduced
ossiﬁcation, especially in the hind paws of mutants (Fig. 5O, P).
However, there are no skeletal patterning defects in the mutants
(Fig. 5M–P). From these results we conclude thatMed31mutants have
a properly patterned limb bud with respect to the AER. However, Sox9
and Col2a1 expression are not detected in Med31 mutant limb buds,
indicating that chondrogenesis is delayed or reduced in Med31
mutants, and identifying Sox9 and Col2a1 as a putative Med31 target
genes.
Discussion
Med31 is required for mammalian development
Here we report the ﬁrst mouse mutant in the Mediator complex
protein Med31. Med31 mutant embryos are smaller than control
littermates from early gestation and do not survive past birth, which
demonstrates that Med31 is an essential gene in mammals. Despite
signiﬁcant sequence conservation with its yeast homolog, this is in
contrast to ﬁndings from S. cerevisiae, where deletion of Soh1/Med31
does not result in lethality (Fan and Klein, 1994). However, yeast
mutants in Med31 do display a slow growth phenotype (Koschubs et
al., 2009). Biochemical analysis demonstrates that the Med31 point
mutation causes degradation of the Med31 protein and that l11Jus15
mutants have no Med31 protein, conﬁrming that the l11Jus15mutant
mouse represents a Med31 null phenotype. Recent crystal structure
data demonstrate that the yeast Med31 homolog has a novel protein
fold and that Med31 directly binds Med7 (Koschubs et al., 2009). We
predict that mouse Med31 would have a similar structure to yeast
Med31 due to the high sequence similarities between the two
proteins.
Comparison with other Mediator complex mutants
Individual protein components of the Mediator complex may
interact with speciﬁc transcription factors to control the expression of
distinct groups of genes during development. Support for this
hypothesis comes from the variable phenotypes of different Mediator
complex mouse mutants. Unlike mouse mutants of the Mediator
complex proteins Med1/TRAP220 and Med24/TRAP100 (Ito et al.,
2002, 2000; Stumpf et al., 2006), Med31 mutants displayed no
apparent erythropoiesis, cardiac, or neural developmental defects.
Med31 mutants also survive until late gestation, whereas Med1/
TRAP220−/− andMed24/TRAP100−/− embryos do not (Ito et al., 2002,
2000). Notably, both Med1/TRAP220 and Med24/TRAP100 interactspho-histone H3 levels at E9.5 (A), but not E10.5 (B), relative to both wild-type and
mm2, ANOVA and post hoc test, pb0.05). The greatest difference observed was in E10.5
demonstrates that the vasculature of mutant embryos is comparable to that of controls
shown for wild type (+/+), heterozygote (+/−), and Med31 mutant (−/−) mouse
es in cell number between wild-type, heterozygote, and mutant ﬁbroblasts on days 3, 5,
reveal no differences between heterozygous and wild-type littermates but signiﬁcant
lysate reveals Cdc2, but not Cdk2, protein levels are reduced in most mutant samples. A
hole embryos demonstrate that Cdc2 levels are similar in both mutants and wild-type
mutants as compared to wild-type littermates (t-test, p=0.65). (M) Quantitative PCR
xpression is signiﬁcantly reduced in Med31 mutants (t-test, p=0.03), while Mustn1
m.
Fig. 5.Med31mutants have limb development defects. (A) Fgf-8 expression in a control littermate marks the AER of the limb bud (arrows). (B)Med31mutants express Fgf-8 in the
AER of both the forelimb and hindlimb (arrows, n=4). (C) Sox9 is expressed in the developing limb bud of control littermates at E10.5 (arrow). (D) Med31 mutants lack Sox9
expression in the limb bud (arrow) but retain expression in the neural tube, otic vesicle, and branchial arches (n=3). (E) Control littermates have a properly formed otic capsule
(arrow). (F) Med31 mutants have an otic capsule that is morphologically indistinct from control littermates (arrow, n=3). (G) Control littermates have Col2a1expression in the
developing limb bud at E10.75 (arrow). (H) Col2a1 limb bud expression is absent inMed31mutant (arrow, n=3). (I, K) Control littermates at E14.5 have a central ossiﬁed region in
the developing bones of the forelimb (arrow). (J, L)Med31mutants have smaller bones that lack an ossiﬁed central region (arrow). (M) Control littermates at E18.5 are larger in size
than mutants. The size difference is pronounced in the forelimb (arrow). (N) Med31 mutant has an overall smaller skeleton than control littermate, although bone has developed
throughout the skeleton. The size difference is notable in the forelimbs of themutants (arrow, n=3). (O) The hind paw of a control littermate shows three ossiﬁed bones in each digit
(arrows). (P) The hind paw of a mutant shows only one ossiﬁed bone in each digit (arrow, n=3). Scale bar=1 mm.
154 M.D. Risley et al. / Developmental Biology 342 (2010) 146–156with thyroid hormone receptors (Yuan et al., 1998; Zhang and
Fondell, 1999), an activity that has never been detected for Med31.
However, primary ﬁbroblast cells from Med1/TRAP220−/−, Med24/
TRAP100−/−, and Med31 mutant embryos all have proliferation
defects. The proliferation defects observed in the Med1/TRAP220
and Med24/TRAP100 mutants may result from blocking nuclear
hormone receptor signaling (Ito et al., 2000). As Med31 has notbeen identiﬁed as a nuclear hormone receptor interacting protein, it is
unlikely that impaired receptor signaling accounts for the prolifera-
tion defects in Med31 mutant embryos and ﬁbroblasts.
We ﬁnd that target genes of other Mediator complex proteins,
such as Med1/Trap220 and Med28, are not mis-expressed in Med31
mutants. This provides support for the hypothesis that individual
Mediator complex proteins can regulate the expression of distinct
155M.D. Risley et al. / Developmental Biology 342 (2010) 146–156sub-sets of target genes. It also suggests that Med31 is not required for
general transcriptional activation, but rather has a speciﬁc function in
the activation of genes related to embryonic growth and cell
proliferation. Further examination of individual Mediator complex
proteins is needed to identify speciﬁc interaction partners, target
genes, and developmental roles for each Mediator complex protein.
The role of Med31 in cell proliferation
Med31 mutants display growth defects when compared to
heterozygous littermates, exhibiting an overall smaller body size
with delays in development. Our data demonstrate that Med31
mutants also have reduced Cdc2 protein levels. Cdc2 is the only
essential cell cycle Cdk (Santamaria et al., 2007). In complex with
cyclin A, Cdc2 is responsible for progression through the G2 phase of
the cell cycle. Additionally, interactions between cyclin B and cdc2
promote entry into M phase (Budirahardja and Gonczy, 2009).
Inhibition of Cdc2 in MEFs results in a failure to enter mitosis
(Nakayama et al., 2004). Thus, the reduction in Cdc2 protein levelsmay
cause the proliferation defects observed in Med31 mutant embryos
and ﬁbroblasts. We also detect a reduction in cyclin B expression in
Med31mutants, providing further support for the conclusion that cell
cycle abnormalities result from a lack of Med31 function.
Although Med31 expression levels are highest in the developing
brain, we found a more pronounced cell proliferation defect in the
limb bud. This may be due to higher overall levels of cell proliferation
in the limb bud as compared to the brain, which we observe even in
wild-type embryos (Fig. 4B). Differences in proliferation rates may
therefore appear more pronounced in regions with a greater
requirement for cell proliferation. However, the proliferation defects
found in our mutant embryos indicate that Med31 is required during
limb development, and indeed, Med31 is also highly expressed in the
developing limb. The chondrocyte marker genes Sox9 and Col2a1 have
expression defects in the Med31 mutant limb bud. Med31 mutants
lack Sox9 expression only in the limb bud, and development of other
structures that require Sox9, such as the ear, is not affected in Med31
mutants. In zebraﬁsh, Sox9 is activated by Med12/Trap230 (Rau et al.,
2006), which is found in the variable Cdk8 Mediator module (Malik
and Roeder, 2005). As Med31 is located in the middle region of the
Mediator complex (Malik and Roeder, 2005), and in yeast has novel
protein folds predicted to be conserved with mammalian Med31
proteins (Koschubs et al., 2009), it is unlikely that Med31 andMed21/
Trap230 would have a similar structural conformation. It is therefore
possible that interactions between Med31 and a limb-speciﬁc
transcription factor activate Sox9 in the limb bud, while interactions
between Med12/Trap230 and a different transcription factor with a
different binding surface interact to activate Sox9 expression in the ear
and neural crest.
We propose that in mammals, Med31 functions during develop-
ment to activate genes required for fetal growth and proliferation, a
phenotype that could not be predicted fromMed31mutations in other
organisms. The variation in phenotypes caused byMed31mutations in
yeast, Drosophila, and mouse, as well as the distinct phenotypes
observed betweenmouse Mediator complex mutants, and the normal
expression of other Mediator complex target genes inMed31mutants,
highlights the unexpected complexity of the functions of theMediator
complex during development.
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